Latest on Pharmaceutical Industry


Shandong Buchang Pharmaceuticals unit receives approval for drug clinical trials

Shandong Buchang Pharmaceuticals Co Ltd Says its unit has been granted approval for drug clinical trials for BC0335 APIs and BC0335 granules issued by china food and drug administration. BC0335 is used for treatment o..Read More...

Cardiome announces licensing agreement for xydalba to support planned commercialization in Israel

Cardiome announces licensing agreement for xydalba™ (dalbavancin hydrochloride) to support planned commercialization in Israel. Cardiome Pharma Corp - signed an exclusive license and distribution agreement with tzamal ..Read More...



Pharma CiMi.CON 2017

Maritim proArte Hotel Berlin,
we.CONECT Global Leaders



Kameha Grand Bonn,
inspirato Conferences

Press Releases

NovellusDx Announced Today the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523

NovellusDx announced today the completion of the first phase of an invitro study to characterize the functional activity of ERK12 mutations and their response to BioMed Valley Discoveries39 lead compound BVD523 The MA.. Read More...

Tolero Pharmaceuticals to Expand Enrollment of Phase II Study of Alvocidib in MCL-1-Dependent AML into Europe

Tolero Pharmaceuticals Inc a clinicalstage company developing treatments for serious hematological diseases today announced that it is adding European study centers to its ongoing Phase II clinical trial evaluating alvoc.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics